Search

Search Constraints

You searched for: Author/Creator Hochmair, M J

Search Results

1. 1464PKEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. (23rd October 2018)

3. 466OASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test. (25th November 2018)

6. LBA15Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia. (24th November 2019)

7. LBA1Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial. (24th November 2019)

8. LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN. (15th December 2019)

9. LBA58Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. (23rd October 2018)